Aryl urea analogs with broad-spectrum antibacterial activity.
The preparation and evaluation of novel aryl urea analogs as broad-spectrum antibacterial agents is described. Numerous compounds showed low micromolar minimum inhibitory concentrations (MIC) against both Gram-positive and Gram-negative bacteria. Selected analogs also exhibited in vivo efficacy in a lethal murine model of bacterial septicemia.
Ibis Therapeutics, A Division of Isis Pharmaceuticals, Inc., 1891 Rutherford Road, Carlsbad, CA 92008, USA. pseth@isisph.com
Punit P
PP
Seth
Ray
R
Ranken
Dale E
DE
Robinson
Stephen A
SA
Osgood
Lisa M
LM
Risen
Elizabeth L
EL
Rodgers
Michael T
MT
Migawa
Elizabeth A
EA
Jefferson
Eric E
EE
Swayze
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis / Q000494:pharmacology; D005069:Evaluation Studies as Topic; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000254:growth & development; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D013329:Structure-Activity Relationship; D013890:Thiourea / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D013890:Thiourea